{
  "id" : "n_myc_amplification_57417",
  "algorithm" : "pediatric",
  "version" : "1.0",
  "name" : "n-MYC Amplification",
  "title" : "n-MYC Amplification",
  "notes" : "**Note 1:** This SSDI is effective for diagnosis years 2024+\n* For cases diagnosed 2018-2023, leave this SSDI blank\n\n**Note 2:** n-MYC Amplification is a gene that normally regulates cell growth. Studies have shown that n-MYC amplification is an indicator of poor prognosis and increased risk of unfavorable outcomes in patients with neuroblastoma.\n* Primary sources of information: molecular pathology report (may be addendum to original pathology report), CAP Protocol\n\n**Note 3:** Physician statement of n-MYC can be used to code this data item when no other information is available.",
  "footnotes" : "(1) American Society of Clinical Oncology Â© 2009, The International Neuroblastoma Risk Group (INRG) Classification System: AN INRG Task Force Report; published by American Society of Clinical Oncology, 2009",
  "last_modified" : "2023-09-26T16:41:21.225Z",
  "definition" : [ {
    "key" : "n_myc_amplification",
    "name" : "Code",
    "type" : "INPUT"
  }, {
    "key" : "description",
    "name" : "Description",
    "type" : "DESCRIPTION"
  } ],
  "rows" : [ [ "0", "Not amplified/negative" ], [ "1", "Amplified/positive" ], [ "2", "Gain" ], [ "7", "Test ordered, results not in chart" ], [ "8", "Not applicable: Information not collected for this case\n(If this information is required by your standard setter, use of code 8 may result in an edit error)" ], [ "9", "Not documented in medical record\nCannot be determined by pathologist\nNot applicable (secondary to previous chemotherapy)\nn-MYC not assessed or unknown if assessed" ], [ "", "N/A - Diagnosis year is prior to 2024" ] ]
}